Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Scientists worldwide are testing a wide range of potential vaccines to counter melanoma, the deadliest form of skin cancer that claims thousands of lives each year. Promising early results were reported at the fourth World Conference on Melanoma in Sydney this week, although researchers warned the technology was still in its early stages.
"Vaccines are the hope of the future for the prevention of recurrence of melanoma," said Professor William McCarthy of Sydney's Royal Prince Alfred Hospital.
More than 90,000 new cases of melanoma are reported around the world each year, about 6,000 in Australia, which has the highest incidence of the lifestyle-related disease.
The traditional treatment is to remove tumours by surgery, but the new hope is to combine surgery with a therapeutic vaccine, manufactured from the tumourous cells, to boost the body's immune system and help it attack the disease.
Vaccine trials are focussing on patients with a 50 per cent risk of recurrence.Early results reported to the conference found patients given the vaccine lived 17 percent longer than those who had surgery only, although the trial is not yet complete.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments